ONWARD
ONWARD today announced Andy Dolan, a marketing executive with 20 years’ health sector experience, has joined the company as Vice President of Marketing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005003/en/
“Given his track record of achievement driving marketing and commercial strategy, we are thrilled to have Andy join our team,” said Dave Marver, Chief Executive Officer of ONWARD. “Andy understands the unique needs of people with spinal cord injury. His expertise and passion will be invaluable as we advance in our quest to develop and scale ONWARD’s breakthrough therapies.”
Andy comes to ONWARD from ReWalk Robotics where, most recently, he served as Vice President of Marketing and Reimbursement. In this role, he led global product marketing, communications, U.S. reimbursement and new business development for the company. Prior to that, he held roles in marketing and product management.
Andy’s deep experience also includes time at Boston Scientific and Johnson & Johnson, where he held commercial and product management roles with a focus on educating providers and increasing patient access to treatments.
“Throughout my career, my personal mission has been to understand unmet needs and work to provide access for patients who desperately need innovations to improve their quality of life,” said Dolan. “I’m excited to marry my personal mission with that of ONWARD to advance promising therapies for those living with spinal cord injury.”
Andy received his undergraduate degree from Springfield College and holds an MBA from University of Massachusetts, Amherst. In addition, Andy received his graduate certificate in bioengineering from Tufts University.
About ONWARD
ONWARD (@onwdempowered
) is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARC-IM and ARC-EX. The company’s first FDA pivotal trial, called Up-LIFT, commenced in January 2021 with plans to enroll 65 subjects at up to 15 centers worldwide.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands and the EPFL Innovation Park in Lausanne, Switzerland, with a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005003/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
WEF26: Saudi Arabia Leads New Global Push to Protect Coral Reefs, Unlock AI Potential22.1.2026 05:52:00 CET | Press release
The Saudi delegation to the World Economic Forum (WEF) Annual Meeting 2026 today observed a series of announcements aimed at addressing urgent global challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121465066/en/ Her Royal Highness Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, announced at the World Economic Forum Annual Meeting that Saudi Arabia will host the first Global Coral Reef Summit in 2026 (Photo: AETOSWire) Her Royal Highness Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, announced that Saudi Arabia will host the first Global Coral Reef Summit in 2026, bringing together global leaders, scientists, and investors to drive solutions for the protection and recovery of coral reef ecosystems. The summit will address key challenges and policy and regulatory gaps, develop science-based sol
BitGo Holdings Announces Pricing of Initial Public Offering22.1.2026 03:38:00 CET | Press release
BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, announced today the pricing of its initial public offering of an aggregate of 11,821,595 shares of Class A common stock at a price to the public of $18.00 per share. The offering consists of 11,026,365 shares of Class A common stock being offered by BitGo and 795,230 shares of Class A common stock being offered by certain existing stockholders of BitGo. BitGo will not receive any proceeds from the sale of the shares by the selling stockholders in connection with the offering. In connection with the offering, BitGo has granted the underwriters a 30-day option to purchase up to an additional 1,770,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on January 22, 2026 under the ticker symbol "BTGO" and the offering is expected to close on January 23, 2026, subject to customary closin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom